Oncology
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
The new perioperative regimen cuts death risk by 42% in cisplatin-ineligible patients, marking a major expansion for AstraZeneca’s oncology portfolio.
-
How the OncoMate MSI Dx Test Guides Pembrolizumab Therapy
Discover how the OncoMate MSI Dx test uses PCR technology to identify MSI-H solid tumors and match patients with pembrolizumab immunotherapy.
-
Experimental Drug Combo Doubles One-Year Survival Rates in Pancreatic Cancer Trial
A new study shows that adding an experimental drug to standard chemotherapy significantly improves survival outcomes for patients with metastatic pancreatic cancer.
-
Why Oncology Trials Chase Surrogate Endpoints the FDA Ignores
An analysis of how trial designs focused on immune response metrics bypass FDA requirements, potentially delaying approvals for lifesaving cancer combinations.
-
SABR Versus Surgery: New Study Reveals Mortality Gap for Early-Stage Lung Cancer
Large population study finds SABR linked to higher three-year mortality than surgery, but gap narrows significantly for patients 80 and older.
-
How Amivantamab’s Dual EGFR-MET Blockade Overcomes Resistance in Head and Neck Cancer
The first new drug in a decade for advanced HNSCC uses a bispecific antibody to hit two escape pathways at once, doubling…
-
START Opens First Italian Early-Phase Cancer Trial Site in Rome
Strategic partnership establishes first START site in Italy, expanding early-phase cancer trial access to patients in Rome and the Lazio region despite…
-
Personal Factors Driving Cancer Biomarker Decisions and Patient Outcomes
Gosselaar’s campaign highlights how personal health history and financial access shape biomarker testing choices and treatment precision.
-
Histotripsy: FDA Clears Non-Invasive Cancer Treatment, HOPE4LIVER Trial Shows Promising Results
Histotripsy, a non-invasive ultrasound therapy, is now FDA-approved for liver tumors. The HOPE4LIVER trial showed local control rates and safety profiles, but…
-
CAR-T Cell Therapy Explained: How It Works, Approved Blood Cancers, and Key Risks
An oncologist’s viral reel calls it revolutionary; here is the plain guide to the treatment, its FDA-approved uses, response data, and serious…
-
BMS RYZ101 Meets Phase 3 Goal in Neuroendocrine Tumors After Lutetium-177 Failure
Bristol Myers Squibb reports its actinium-225 therapy met primary endpoint in ACTION-1 trial, offering hope for a narrow group of patients.
-
New Study Shows Tucatinib Delays Progression in Breast Cancer Spread to Brain
A Duke-led trial found adding tucatinib to standard care substantially delayed worsening in HER2-positive breast cancer patients with new brain metastases.
-
GSK to Nearly Double Cancer Drugs in Trials as It Rebuilds Oncology Ahead of HIV Patent Cliff
Amidst looming patent expirations for HIV blockbusters, GSK is aggressively expanding its oncology pipeline, aiming to double late-stage cancer drug studies by…
-
Why Microsatellite Instability Status Dictates Rectal Cancer Treatment Choices
MSI-H status identifies rectal cancer patients who may avoid surgery via dostarlimab, a new FDA-approved immunotherapy targeting defective DNA repair.
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
The FDA’s August 2026 approval of iberdomide introduces a new class of cancer drugs for patients with relapsed or refractory multiple myeloma.
-
How Liquid Biopsy Is Transforming Cancer Monitoring and Early Detection Strategies
Non-invasive blood tests are moving beyond niche use to become vital tools for tracking treatment response, detecting recurrence, and screening for cancer.
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
The 2026 AACR Cancer Progress Report highlights a rise in survival rates and the emergence of innovative drug classes like PROTACs and…
-
European Regulators Back Breakthrough Pancreatic Cancer Drug Rasonque
The EMA has recommended approval for daraxonrasib, a daily pill that doubles survival rates for patients with metastatic pancreatic adenocarcinoma.
-
How a Hidden Fat-Sensing Protein Could Unlock Immunotherapy for Deadly Colorectal Cancers
A new study reveals how tweaking a single molecular switch in immune cells could turn ‘untreatable’ tumors into immunotherapy responders—without headlines.
-
Zanidatamab’s Dual-Targeting Design Offers Alternative To Trastuzumab Deruxtecan
Zanidatamab’s unique mechanism and clinical data show promise for HER2-positive cancer treatment
-
NCCN Adds Anktiva Plus BCG for Papillary-Only, BCG-Unresponsive Bladder Cancer
Silver Spring, October 16 — On October 14, 2026, the U.S. Food and Drug Administration approved an expanded use of nogapendekin alfa…
-
FDA expands Anktiva approval to cover papillary-only bladder cancer, first treatment for this group
The FDA has broadened Anktiva’s use with BCG to include patients with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, offering a bladder-preserving option…
-
GammaTile Trial Shows 1.3% Recurrence at One Year Versus 15.4% After Standard Radiation
HOUSTON, October 2 — GT Medical Technologies announced on September 29, 2026, that the results of the randomized, multicenter ROADS trial (NCT04365374)…
-
Immunotherapy Emerges as the Fourth Pillar of Cancer Care, Experts Say
ISLAMABAD, September 20 — Cancer immunotherapy, the approach that harnesses the body’s own immune system to fight tumours, has become the fourth…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992